Inquiry Basket
CAS No.:
Cat No.: BADC-01463
4.5 
Azide-PEG4-VC-PAB-Doxorubicin is composed of linker Azide-PEG4-VC-PAB and toxic molecule Doxorubicin, which can be used to prepare antibody-conjugated drugs.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Azide-PEG4-VC-PAB-Doxorubicin is a chemically conjugated compound integrating a chemotherapeutic agent with a linker for targeted drug delivery. Here are some key applications of Azide-PEG4-VC-PAB-Doxorubicin:
Targeted Cancer Therapy: Azide-PEG4-VC-PAB-Doxorubicin allows for the specific delivery of doxorubicin to cancer cells by attaching to targeting moieties such as antibodies or peptides. This targeted approach minimizes the side effects typically associated with conventional chemotherapy. As a result, patients potentially experience greater efficacy with reduced toxicity.
Bioconjugation Studies: The azide functional group facilitates the conjugation of Azide-PEG4-VC-PAB-Doxorubicin to various biomolecules through click chemistry. This is particularly useful for developing targeted therapies as it allows for the seamless attachment of the drug to a wide array of targeting agents. Researchers can explore different targeting strategies to improve drug specificity and therapeutic outcomes.
Overcoming Drug Resistance: Azide-PEG4-VC-PAB-Doxorubicin can be used to circumvent multi-drug resistance mechanisms in cancer cells. The PEGylation and specific linkage strategy help in evading drug efflux pumps, which are often upregulated in resistant cancer cell lines. This approach enhances the intracellular concentration of doxorubicin, improving its cytotoxic effectiveness against resistant tumors.
Pharmacokinetic Optimization: The incorporation of the PEG4 linker in Azide-PEG4-VC-PAB-Doxorubicin improves the pharmacokinetics of the drug, such as increased circulation time and reduced immunogenicity. This leads to better accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Optimizing these pharmacokinetic properties is crucial for improving the overall therapeutic index of doxorubicin-based treatments.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00892 | N-(Iodoacetamido)-Doxorubicin | 114390-30-6 | |
| 1547491-85-9 | N-([1,1'-biphenyl]-4-yl)-[1,1':3',1''-terphenyl]-4'-amine | 1547491-85-9 | |
| BADC-00042 | Daunorubicin | 20830-81-3 | |
| BADC-00039 | Doxorubicin | 23214-92-8 | |
| BADC-00038 | Doxorubicin hydrochloride | 25316-40-9 | |
| BADC-01122 | Doxorubicin-SMCC | 400647-59-8 | |
| BADC-00363 | Aldoxorubicin hydrochloride | 480998-12-7 | |
| BADC-01412 | MA-PEG4-VC-PAB-DMAE-Doxorubicin | ||
| BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | ||
| BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin |
Azide-PEG4-VC-PAB-Doxorubicin
Required fields are marked with *
Azide-PEG4-VC-PAB-Doxorubicin
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
